KALA
KALA BIO, Inc.NASDAQHealthcare$0.17+4.42%ClosedMarket Cap: $3.7M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.14
P/S
14.93
EV/EBITDA
-0.44
DCF Value
$3.33
FCF Yield
-846.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3.1%
Operating Margin
-15055.9%
Net Margin
-14110.6%
ROE
-2323.9%
ROA
-143.2%
ROIC
-179.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $0.00 | $-7.6M | $-1.07 |
| Q2 2025 | $0.00 | $-11.2M | $-1.71 |
| Q1 2025 | $0.00 | $-8.9M | $-1.41 |
| Q4 2024 | $254.0K | $-8.2M | $-1.74 |
Analyst Ratings
View AllHC Wainwright & Co.Neutral
2025-09-29HC Wainwright & Co.Buy
2025-09-17OppenheimerOutperform
2025-09-11HC Wainwright & Co.Buy
2025-05-23HC Wainwright & Co.Buy
2025-04-04Trading Activity
Insider Trades
View AllPurdy Brendan P.director:
SellMon Feb 09
Posen Hillel D.director:
SellMon Feb 09
Minkowitz Avrahamdirector, officer: Chief Executive Officer
SellMon Feb 09
Colman Yonatan C.director:
SellMon Feb 09
Berger Chaim D.director:
SellMon Feb 09
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
-1.99
Kala Bio, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of therapeutics using proprietary nanoparticle-based mucus penetrating particles with an initial focus on the treatment of eye diseases. The company was founded by Justin Hanes, Robert S. Langer and Colin R. Gardner in 2009 and is headquartered in Arlington, MA.